TD Cowen Insights

TD Securities, TD Cowen
  • 4.8 (36)
  • BUSINESS
  • UPDATED WEEKLY

On each episode of "TD Cowen Insights", members of our firm host leading thinkers to share insights and ideas shaping the world economy. Join us, as we converse with the top minds who are influencing our global sectors. Disclosures: https://go.td.com/PodcastDisclosure

  1. MAR 20

    Bio-Techne at 50: CEO Kim Kelderman's Reflection on Five Decades of Platform Evolution & Strategic Priorities Ahead

    Recorded on 03/03/26 TD Cowen life science & diagnostic tools analyst Kyle Boucher speaks with Bio-Techne CEO Kim Kelderman at TD Cowen's 46th Annual Health Care Conference to discuss Bio-Techne's 50-year anniversary, innovation and portfolio evolution, and growth pillars ahead. Since 1976 Bio-Techne has offered a wide range of critical reagents, assays, and analytical tools for customers in diagnostic, pharma, biotech, and academic settings, and has created one of the most consumables-focused portfolios in life science tools. CEO Kelderman reflects on Bio-Techne's 50-year history, including the last 10 years where the portfolio has grown through several inorganic acquisitions addressing multiple high-growth verticals that have laid the foundation for the next leg of growth. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    14 min

  2. MAR 20

    CEO Meeker & CFO Smith's Strategy To Build Rhythm Into The Leading Orphan Obesity Company

    Recorded on 03/01/26 TD Cowen senior biotech analyst Phil Nadeau speaks with Rhythm CEO David Meeker and CFO Hunter Smith at TD Cowen’s 46th Annual Health Care Conference to discuss Rhythm's strategic vision for establishing itself as the premier company in the orphan obesity space. Rhythm leverages the melanocortin pathway to address severe, early-onset obesity disorders, and its strategy is structured around three main pillars: genetic obesities, hypothalamic obesity (HO), and Prader-Willi syndrome. Building on the successful launch of Imcivree in Bardet-Biedl syndrome (BBS), Rhythm is now preparing for what may be its most significant launch to date: Imcivree for the treatment of hypothalamic obesity. Rhythm is optimistic that Imcivree will set a new standard of care for HO, significantly improve patient outcomes, and generate considerable value for shareholders. Beyond HO, Meeker and Smith outlined additional opportunities for Rhythm’s melanocortin-4 receptor (MC4R) agonists in other rare obesity disorders. These include ongoing investigations in various genetic obesity conditions as part of the Phase III EMANATE trial, as well as progress in Prader-Willi syndrome, where Imcivree demonstrated proof-of-concept efficacy in late 2025. To ensure the long-term success of the MC4R franchise, Rhythm is advancing a comprehensive life cycle management strategy, which includes the clinical development of next-generation MC4R agonists such as bivamelagon and RM-718. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    12 min

  3. MAR 18

    FDA Engagement and the Evolving Psychedelic Therapy Landscape: A Conversation with Compass Pathways CEO Kabir Nath

    Recorded on 03/03/26 TD Cowen senior biotech analyst Ritu Baral speaks with Compass CEO Kabir Nath at TD Cowen’s 46th Annual Health Care Conference. Discussion focused on FDA’s current approach to psychedelic drug development, what it signals for the broader psychiatry landscape, and the evolving interventional psychiatry infrastructure in the community setting. Nath highlights a highly engaged and collaborative FDA Psychiatry Division, noting the agency's recent acceptance of 7-8 psychedelic therapy INDs, and its willingness to work constructively with sponsors despite relatively small datasets in early development. He highlights recent positive psychedelic clinical datasets as many traditional antidepressant approaches continue to fall short, including Compass’s successful Phase 2 and 3 TRD results across three standardized studies as evidence of the category’s clinical potential. The conversation also explores how the existing interventional psychiatry infrastructure in the community setting, shaped in part by the successful launch of Spravato, has transformed the field and lowered barriers for future commercial uptake of innovative psychedelic therapies. With 7200+ certified Spravato treatment sites now in place and increasing familiarity with REMS-based models, Nath emphasizes the importance of bringing forward additional options in the psychedelic space to address significant unmet need across MDD, TRD, and PTSD as psychiatry treatment paradigms continue to evolve. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    6 min

  4. MAR 18

    Click Therapeutics & Software-Enhanced Drugs

    Recorded on 03/03/26 TD Cowen FutureHealth Podcast is part of TD Cowen's ongoing series that continues our efforts to bring together thought leaders, innovators, and investors to discuss how the convergence of healthcare, technology, consumerism, and policy is changing the way we look at health, healthcare, and the healthcare system. To discuss the role of digital therapeutics in the ongoing consumerization of healthcare, we're joined by Randall Stanicky, CFO of Click Therapeutics. We discuss the evolution of the digital therapeutics market, Click's partnerships with Otsuka and wearables company Ultrahuman, and Click's potential role in the continuing consumerization of healthcare. This episode was recorded at TD Cowen's 46th annual Health Care Conference. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    13 min

  5. MAR 18

    Congress & White House Put Focus On Help For Housing

    Recorded on 03/17/26 TD Cowen financial policy analyst Jaret Seiberg hosts this episode, which looks at Washington's focus on housing policy, including legislation that the Senate recently passed and executive orders that President Trump signed. We also get a market update from TD Cowen specialty salesperson Scott Smith. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    21 min

  6. MAR 13

    Two Weeks Of Epic Fury

    Recorded on 03/13/26 In this episode, Roman Schweizer, TD Cowen’s WRG geopolitics & defense analyst, is joined by a dynamic duo of reporters to discuss the first two weeks of Operation Epic Fury. They also discuss the outlook for an OEF war supplement for munitions and other costs, and the War Department's FY27 budget request and the possibility of a 2nd GOP reconciliation bill. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    33 min

  7. MAR 12

    What's Next for Charles River?

    Recorded on 03/03/26 There's no shortage of debates in the CRO space right now: the impact of regulatory changes, a potentially rebounding macro environment, and, most recently, the implications of AI. We're joined by Birgit Girshick, current Executive Vice President, Chief Operating Officer, and incoming CEO of Charles River Labs. We discuss her vision and key priorities for CRL, the biggest recent changes she's seen in the industry, the potential impact of AI, and where she sees the largest strategic opportunities. This episode was recorded at TD Cowen's 46th annual Health Care Conference. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    13 min

  8. MAR 12

    Transforming Human Health With Advanced Diagnostics: A Conversation With Radence CEO David Medvedeff

    Recorded on 02/25/26 Five years ago, concierge medicine was on the fringes of society, and now it's mainstream. Radence, a leading precision health company, moves the goal posts further by focusing on "concierge science." In this podcast, we explore what concierge science means with the CEO of Radence, David Medvedeff. Radence's unique approach leverages a team of leading scientists to identify the best cutting-edge technologies for its members. The company seeks to provide the critical testing, monitoring, and strategic precision medicine overlay to support and enhance forward-thinking PCPs who seek to extend health span and reduce chronic illness. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    10 min
See All (349)

4.8
out of 5
36 Ratings

About

On each episode of "TD Cowen Insights", members of our firm host leading thinkers to share insights and ideas shaping the world economy. Join us, as we converse with the top minds who are influencing our global sectors. Disclosures: https://go.td.com/PodcastDisclosure

Information

  • Creator
    TD Securities, TD Cowen
  • Years Active
    2020 - 2026
  • Episodes
    349
  • Rating
    Clean
  • Copyright
    © TD Securities
  • Show Website
    TD Cowen Insights

You Might Also Like